Try GOLD - Free

BIOTECH: Blood, Sweat and Tears

Newsweek US

|

February 14, 2025

Nine years in the making, Truvian's quick tabletop blood test promises to deliver where Theranos famously couldn't

- ALEXIS KAYSER

BIOTECH: Blood, Sweat and Tears

IN SEPTEMBER 2015, DR. DENA MARRINUCCI set out to perfect a tabletop device that could rapidly test a small amount of blood, returning results in under 30 minutes. If the concept sounds familiar, that's because it is. She wasn't the only one with ambitions to transform the laboratory industry.

The month after Marrinucci co-founded Truvian, The Wall Street Journal published an expose accusing Theranos-Truvian's now infamous, defunct competitor of misrepresenting the accuracy and reliability of its own blood-testing technology, while deceiving doctors, patients and investors. At the time, Theranos was valued at $9 billion.

The Journal's investigation set off a domino effect. Theranos lost its license and last summer its CEO, Elizabeth Holmes, began an 11-year prison sentence.

When Truvian launched in 2015, Marrinucci had six months of seed money from venture capiby tal firm Domain Associates and plans to raise a larger round quickly. But after the Theranos debacle, Truvian needed more than proof of concept. It needed proof of candor.

"We recruited some of the naysayers of Theranos, very high-profile opinion leaders in the laboratory medicine space," Marrinucci told Newsweek. "We said, let's bring them onto our team and learn from them and understand their skepticism, and have them help us review data from the very onset of the company." It took two years for Truvian to close its Series A funding round and begin refining its tabletop laboratory device. About six years and eight months later, I was rolling up my sleeve to test it out myself.

My Rapid Blood Test

I first met Marrinucci and Jay Srinivasan, Truvian's CEO, on September 6, 2024. They'd set up shop in a Chicago suite belonging to DNS Capital, one of Truvian's investors.

The FDA hadn't (and still hasn't) approved the company's platform, so I had to enroll in a "pilot study" before using it.

MORE STORIES FROM Newsweek US

Newsweek US

Newsweek US

STRAIGHT FROM THE HEART

Kenny Chesney's grit and authenticity have earned him a string of hits and a legion of fans-his No Shoes Nation. Yet despite his induction into the Country Music Hall of Fame, the singer-songwriter isn't slowing down

time to read

11 mins

November 14, 2025

Newsweek US

Newsweek US

Hungry for Data

Failing to feed Al tools with company knowledge can create a costly learning gap, experts tell Newsweek

time to read

5 mins

November 14, 2025

Newsweek US

Newsweek US

A HEALING GANG

Actor Tim Robbins finds his greatest personal and professional fulfillment in four decades of his theater troupe's prison work

time to read

6 mins

November 14, 2025

Newsweek US

MELISSA PETERMAN

FOR MELISSA PETERMAN, THE FIRST SEASON OF NBC'S HAPPY'S PLACE WAS A dream come true; getting a second season is an embarrassment of riches.

time to read

1 mins

November 14, 2025

Newsweek US

Newsweek US

AMERICA'S TOP ONLINE LEARNING SCHOOLS 2026

DIGITAL LEARNING PROVIDES STUDENTS AND EDUCAtors with more flexibility and personalization than traditional educational settings.

time to read

2 mins

November 14, 2025

Newsweek US

Newsweek US

GLENN CLOSE

CONSIDERING THE NUMBER OF ICONIC WOMEN THAT HAVE WORKED ON RYAN MURphy projects, it’s shocking Glenn Close hasn't.

time to read

1 mins

November 14, 2025

Newsweek US

Newsweek US

Smarter Slumber

The billion-dollar startup working to optimize health with better sleep

time to read

8 mins

November 14, 2025

Newsweek US

The Shrinking C-Suite

Companies are flattening their org charts—and even the top team is feeling the squeeze

time to read

6 mins

November 14, 2025

Newsweek US

Newsweek US

A WAR 'AGAINST THE WESTERN WORLD'

Tensions simmer among neighboring NATO countries amid Russia's nearly 4-year-old conflict with Ukraine. Estonian President Alar Karis urges preparation for a 'different kind' of conflict

time to read

6 mins

November 14, 2025

Newsweek US

Newsweek US

PATRICIA ARQUETTE

EVEN BEFORE PATRICIA ARQUETTE SIGNED ON TO PLAY MAGGIE MURDAUGH in Hulu's Murdaugh: Death in the Family, she was already \"obsessed\" with the infamous case of convicted murderer Alex Murdaugh.

time to read

1 mins

November 07, 2025

Listen

Translate

Share

-
+

Change font size